Neuraxis Plunges 11.53% as Investors Take Profits

On May 21, 2025, Neuraxis experienced a significant drop of 11.53% in pre-market trading, marking a notable decline after recent surges.

Neuraxis's recent stock performance has been influenced by several key developments. The company's shares surged following a significant breakthrough in their AI technology, which led to a 120.7% increase in trading. Additionally, the U.S. Food and Drug Administration granted clearance to expand the use of Neuraxis's IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia, resulting in a more than 112% climb in shares.

However, the recent decline in pre-market trading suggests that investors may be taking profits after the substantial gains. The company's stock has shown volatility, with significant increases followed by corrections, reflecting the market's reaction to both positive news and potential profit-taking.